Statinler, vasküler riskin arttığı son zamanlarda ortaya çıkan Parkinson hastalığında yetersiz kullanılmaktadır: UK Tracking Parkinson ve Oxford Parkinson Hastalığı Merkezi (OPDC) keşif kohortlarından elde edilen bulgular.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

BackgroundCardiovascular disease (CVD) influences phenotypic variation in Parkinson's disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately.ObjectivesTo quantify vascular risk and statin use in recent-onset PD, and examine the relationship between vascular risk, PD severity and phenotype.MethodsCardiovascular risk was quantified using the QRISK2 calculator (high ≥20%, medium ≥10 and ResultsIn 2909 individuals with recent-onset PD, the mean age was 67.5 years (SD 9.3), 63.5% were men and the mean disease duration was 1.3 years (SD 0.9). 33.8% of cases had high vascular risk, 28.7% medium risk, and 22.3% low risk, while 15.2% of cases had established CVD. Increasing vascular risk and CVD were associated with older age (pConclusionsOver 60% of recent-onset PD patients have high or medium cardiovascular risk (meriting statin usage), which is associated with a worse motor and cognitive phenotype. Statins are underused in these patients, compared with those with vascular disease, which is a missed opportunity for preventive treatment.Trial registration numberGN11NE062, NCT02881099.

İlgili konular